EQS-News: Formycon AG / Key word(s): Regulatory Admission/MiscellaneousFormycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA) 29.08.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press.
Formycon and Klinge Biopharma have submitted a biologics license application for FYB203, a biosimilar for Eylea, to the FDA, according to a press release.
EQS-News: Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA) finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
EQS-News: Formycon AG / Key word(s): Conference/MiscellaneousFormycon Announces Participation in International Investor Conferences in Q2/2023 10.05.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // May 10, 2023Formycon Announces Participation in Internationa.